Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs BHP Billiton Limited (BHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs BHP Billiton Limited — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while BHP Billiton Limited trades at $90.62 (market cap $229.15B). The key difference: BHP Billiton Limited is far larger — about 7.7× Alnylam Pharmaceuticals, Inc.'s market cap, and BHP Billiton Limited pays a 2.95% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BHP | |
|---|---|---|
Market Cap | $29.60B | $229.15B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $93.15 |
52-Week Low | $205.48 | $52.14 |
Enterprise Value | $27.56B | $243.35B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
BHP trades at $90.38, down 0.25% on the day, with a bullish technical signal driven by moving averages. The company reported Q4 2025 EPS of $2.24, missing expectations of $2.41, but maintains strong profitability with an 18.97% net income margin. Recent news highlights labor strikes at Port Hedland iron ore operations, potentially impacting production, while institutional buying activity signals confidence.
Outlook is mixed: solid fundamentals and copper demand from AI data centers offer growth potential, but strikes and valuation concerns pose risks. Analysts are cautious with 64.52% hold ratings, reflecting balanced near-term uncertainty amid long-term resource strengths.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About BHP Billiton Limited
BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.
Read more on BHP →
